Search

Your search keyword '"Connell, Jeff"' showing total 222 results
Start Over Author "Connell, Jeff"
222 results on '"Connell, Jeff"'

4. Influenza Vaccine Effectiveness Against Symptomatic Influenza in Primary Care: A Test Negative Case Control Study Over Two Influenza Seasons 2022/2023 and 2023/2024 in Ireland.

Author

Marron, Louise, McKenna, Adele, O'Donnell, Joan, Joyce, Michael, Bennett, Charlene, Connell, Jeff, and Domegan, Lisa

Subjects
FLU vaccine efficacy, SEASONAL influenza, VACCINE effectiveness, VACCINATION of children, INFLUENZA vaccines
Abstract

Introduction: Live attenuated influenza vaccine (LAIV) is recommended in Ireland for all children aged 2–17 years. Quadrivalent influenza vaccine (QIV) is recommended for all others eligible for vaccination, including those ≥ 18 years with underlying medical conditions and all aged ≥ 65 years. We aimed to estimate influenza vaccine effectiveness (IVE) against acute respiratory infection (ARI) presentations to primary care due to influenza over two influenza seasons in Ireland, to inform vaccination recommendations and communication campaigns. Methods: We undertook a test‐negative case control study within the Irish sentinel general practice surveillance network as part of the Vaccine Effectiveness Burden and Impact Studies (VEBIS) network. We compared influenza vaccination status among influenza PCR positive cases with influenza PCR negative controls, both with ARI presentations, of all ages. We estimated IVE using logistic regression adjusting for age, onset time, medical conditions and sex. Results: In 2022/2023, there were 288 cases and 765 controls. In 2023/2024, there were 567 cases and 1832 controls. In 2022/2023, overall IVE was 42% (95% CI 9 to 64) and 50% (95% CI −30 to 83) in 2‐ to 17‐year‐olds. Overall IVE in 2023/2024 was 35% (95% CI 15 to 51) and 68% (95% CI 30 to 87) in 2‐ to 17‐year‐olds. Conclusion: Influenza vaccination reduced the risk of influenza among ARI patients presenting to general practice, demonstrating the benefits of vaccination, particularly among children. Promotion of the seasonal influenza vaccine to recommended groups, should remain a public health priority. Targeted vaccination campaigns for children promoting LAIV should emphasise the effectiveness of LAIV in children. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

6. Impact of the COVID‐19 Pandemic on Influenza Circulation During the 2020/21 and 2021/22 Seasons, in Europe

Author

Sinnathamby, Mary A., Meslé, Margaux M. I., Mook, Piers, Pebody, Richard, Bino, Silvia, Hasibra, Iris, Bakunts, Nune, Abovyan, Romella, Khachtryan, Evgenia, Redlberger‐Fritz, Monika, Mursalova, Nazifa, Aliyeva, Firuza, Vysotskaya, Veronika, Shmialiova, Natallia, Karaban, Inna, Bossuyt, Nathalie, Barbezange, Cyril, Musa, Sanja, Vukmir, Nina Rodić, Ljubović, Amela Dedeić, Baštinac, Dijana, Vladimirov, Nadezhda, Korsun, Neli, Trifonova, Ivelina, Tabain, Irena, Petrović, Goranka, Karagiannis, Christos, Haralambous, Christos, Jirincova, Helena, Kyncl, Jan, Trebbien, Ramona, Vestergaard, Lasse Skafte, Sadikova, Olga, Eero, Irina, Metsoja, Eliisa, Ikonen, Niina, Lyytikäinen, Outi, Nohynek, Hanna, Fournier, Lucie, Guerrisi, Caroline, Valette, Martine, Machablishvili, Ani, Buda, Silke, Dürrwald, Ralf, Gioula, Georgia, Mary, Emmanouil, Mellou, Kassiani, Rózsa, Mónika, Molnár, Zsuzsanna, Armannsdottir, Brynja, Aspelund, Guðrún, O’Donnell, Joan, Domegan, Lisa, Connell, Jeff, Mandelboim, Michal, Glatman‐Freedman, Aharona, Puzelli, Simona, Palamara, Anna Teresa, Maraglino, Francesco, Smagulova, Smagulova Meiramgul Kanapiyanovna, Userbayev, Aidar Sharipkhanuly, Kalaveshi, Ariana, Jakupi, Xhevat, Gunga, Zana Kaçaniku, Otorbaeva, D. S, Abdyldaeva, S. Zh, Esengeldiev, G. M, Vasiļevska, Darja, Tomašūna, Kate Karolīna, Savicka, Oksana, Gargasiene, Greta, Muralyte, Svajune, Nguyen, Trung‐Nguyen, Mossong, Joel, Abdelrahman, Tamir T., Melillo, Tanya, Zahra, Graziella, Melillo, Jackie, Rakocevic, Bozidarka, Zekovic, Zeljka, Medenica, Sanja, de Lange, Marit, Meijer, Adam, Kochinski, Dragan, Boshevska, Golubinka, Paulsen, Trinehessevik, Bragstad, Karoline, Brydak, Lidia B., Hallmann, Ewelina, Szymański, Karol, Rodrigues, Ana Paula, Verdasca, Nuno, Guiomar, Raquel, Druc, Alina, Apostol, Mariana, Popescu, Rodica, Popovici, Odette, Lazar, Mihaela, Komissarov, Andrey B., Fadeev, Artem, Stolyarov, Kirill, Protić, Jelena, Avdičová, Mária, Mečochová, Adriana, Staroňová, Edita, Sočan, Maja, Prosenc, Katarina, Berginc, Nataša, Larrauri, Amparo, Mazagatos, Clara, Pozo, Francisco, Appelqvist, Emma, Carnahan, AnnaSara, Cabecinhas, Ana Rita Goncalves, Spedaliero, Tania, Jafarov, Navaruz, Safarova, Tamanno, Barotova, Barno, Kovalchuk, Tatyana, Altas, Ayse Basak, Avci, Emine, Ozdemir, Betul, Ovliyakulova, Gurbangul, Dykhanovska, Tetiana, Demchyshyna, Iryna, Koshako, Oksana, Watson, Conall, Zambon, Maria, Lakhani, Anissa, Shepherd, Samantha, Bradley, Declan T., Curran, Tanya, Moore, Catherine, Cottrell, Simon, Kudasheva, Lyudmila, Djemileva, Sultan, Pleshkov, Boris, Sinnathamby, Mary A., Meslé, Margaux M. I., Mook, Piers, Pebody, Richard, Bino, Silvia, Hasibra, Iris, Bakunts, Nune, Abovyan, Romella, Khachtryan, Evgenia, Redlberger‐Fritz, Monika, Mursalova, Nazifa, Aliyeva, Firuza, Vysotskaya, Veronika, Shmialiova, Natallia, Karaban, Inna, Bossuyt, Nathalie, Barbezange, Cyril, Musa, Sanja, Vukmir, Nina Rodić, Ljubović, Amela Dedeić, Baštinac, Dijana, Vladimirov, Nadezhda, Korsun, Neli, Trifonova, Ivelina, Tabain, Irena, Petrović, Goranka, Karagiannis, Christos, Haralambous, Christos, Jirincova, Helena, Kyncl, Jan, Trebbien, Ramona, Vestergaard, Lasse Skafte, Sadikova, Olga, Eero, Irina, Metsoja, Eliisa, Ikonen, Niina, Lyytikäinen, Outi, Nohynek, Hanna, Fournier, Lucie, Guerrisi, Caroline, Valette, Martine, Machablishvili, Ani, Buda, Silke, Dürrwald, Ralf, Gioula, Georgia, Mary, Emmanouil, Mellou, Kassiani, Rózsa, Mónika, Molnár, Zsuzsanna, Armannsdottir, Brynja, Aspelund, Guðrún, O’Donnell, Joan, Domegan, Lisa, Connell, Jeff, Mandelboim, Michal, Glatman‐Freedman, Aharona, Puzelli, Simona, Palamara, Anna Teresa, Maraglino, Francesco, Smagulova, Smagulova Meiramgul Kanapiyanovna, Userbayev, Aidar Sharipkhanuly, Kalaveshi, Ariana, Jakupi, Xhevat, Gunga, Zana Kaçaniku, Otorbaeva, D. S, Abdyldaeva, S. Zh, Esengeldiev, G. M, Vasiļevska, Darja, Tomašūna, Kate Karolīna, Savicka, Oksana, Gargasiene, Greta, Muralyte, Svajune, Nguyen, Trung‐Nguyen, Mossong, Joel, Abdelrahman, Tamir T., Melillo, Tanya, Zahra, Graziella, Melillo, Jackie, Rakocevic, Bozidarka, Zekovic, Zeljka, Medenica, Sanja, de Lange, Marit, Meijer, Adam, Kochinski, Dragan, Boshevska, Golubinka, Paulsen, Trinehessevik, Bragstad, Karoline, Brydak, Lidia B., Hallmann, Ewelina, Szymański, Karol, Rodrigues, Ana Paula, Verdasca, Nuno, Guiomar, Raquel, Druc, Alina, Apostol, Mariana, Popescu, Rodica, Popovici, Odette, Lazar, Mihaela, Komissarov, Andrey B., Fadeev, Artem, Stolyarov, Kirill, Protić, Jelena, Avdičová, Mária, Mečochová, Adriana, Staroňová, Edita, Sočan, Maja, Prosenc, Katarina, Berginc, Nataša, Larrauri, Amparo, Mazagatos, Clara, Pozo, Francisco, Appelqvist, Emma, Carnahan, AnnaSara, Cabecinhas, Ana Rita Goncalves, Spedaliero, Tania, Jafarov, Navaruz, Safarova, Tamanno, Barotova, Barno, Kovalchuk, Tatyana, Altas, Ayse Basak, Avci, Emine, Ozdemir, Betul, Ovliyakulova, Gurbangul, Dykhanovska, Tetiana, Demchyshyna, Iryna, Koshako, Oksana, Watson, Conall, Zambon, Maria, Lakhani, Anissa, Shepherd, Samantha, Bradley, Declan T., Curran, Tanya, Moore, Catherine, Cottrell, Simon, Kudasheva, Lyudmila, Djemileva, Sultan, and Pleshkov, Boris

Abstract

Background: The emergence of SARS‐CoV‐2 in late 2019 saw the implementation of public health and social measures (PHSM) by countries across Europe to reduce its transmission and impact on populations. Consequently, countries reported changes in influenza circulation and extensive disruptions to routine surveillance systems.MethodsWe describe the epidemiology of influenza in Europe between Weeks 40/2020 and 39/2022 compared to the 2016/17 to 2019/20 seasons, to assess the impact of the COVID‐19 pandemic and PHSM on surveillance systems and influenza circulation.ResultsLow detections of influenza were observed through primary care sentinel sources during seasonal influenza periods (Week 40 to 20); 56 (of 39,457 specimens tested; < 1% positivity) in 2020/21 and 7261 (of 64,153 specimens tested; 11% positivity) detections in 2021/22 were observed, compared to an average of 18,383 (of 50,544 specimens tested; 36% positivity) detections in 2016/17 to 2019/20. Similarly, 11 (of 19,989 specimens tested; < 1% positivity) and 1488 (of 23,636 specimens tested; 6% positivity) detections were reported through SARI surveillance sources in 2020/21 and 2021/22, respectively, compared to an average of 2850 (of 10,389 specimens tested; 27% positivity) detections in 2016/17 to 2019/20. However, the 2021/22 interseasonal period saw unusual increases in influenza detections across surveillance site types when PHSM were easing.ConclusionIn conclusion, findings suggest that the restriction and easing of PHSM measures were associated with variations in influenza detections. Our observations of out‐of‐season influenza activity highlight the importance of an integrated respiratory surveillance strategy to monitor circulating respiratory viruses throughout the year to inform optimal prevention and control strategies.

Published
2024

7. Multi-omics Integration Identifies Genes Influencing Traits Associated with Cardiovascular Risks: The Long Life Family Study

Author

Acharya, Sandeep, primary, Liao, Shu, additional, Jung, Wooseok J., additional, Kang, Yu S., additional, Moghaddam, Vaha A., additional, Feitosa, Mary, additional, Wojczynski, Mary, additional, Lin, Shiow, additional, Anema, Jason A., additional, Schwander, Karen, additional, Connell, Jeff O, additional, Province, Mike, additional, and Brent, Michael R., additional

Published
2024
Full Text
View/download PDF

10. Multiple Introductions of Mpox virus to Ireland during the 2022 International Outbreak

Author

Gonzalez, Gabriel, primary, Carr, Michael, additional, Kelleher, Tomas M, additional, O'Byrne, Emer, additional, Banka, Weronika, additional, Keogan, Brian, additional, Bennett, Charlene, additional, Franzoni, Geraldine, additional, Keane, Patrice, additional, Meredith, Luke W, additional, Fletcher, Nicola, additional, Urtasun-Elizari, Jose Maria, additional, Dean, Jonathan, additional, Crowley, Brendan, additional, Igoe, Derval, additional, Robinson, Eve, additional, Martin, Greg, additional, Connell, Jeff, additional, De Gascun, Cillian F, additional, and Hare, Daniel, additional

Published
2023
Full Text
View/download PDF

12. Establishing severe acute respiratory infection (SARI) surveillance in a sentinel hospital, Ireland, 2021 to 2022

Author

Brady, Melissa, primary, Duffy, Roisin, additional, Domegan, Lisa, additional, Salmon, Abigail, additional, Maharjan, Binita, additional, O'Broin, Cathal, additional, Bennett, Charlene, additional, Christle, James, additional, Connell, Jeff, additional, Feeney, Laura, additional, Nurdin, Nadra, additional, Mallon, Patrick, additional, Doran, Peter, additional, McNamara, Rosa, additional, O'Grady, Sarah, additional, McDermott, Sinead, additional, Petty-Saphon, Naomi, additional, and O’Donnell, Joan, additional

Published
2023
Full Text
View/download PDF

13. Influenza vaccine effectiveness against influenza A subtypes in Europe: results from the 2021–22 I-MOVE primary care multicentre study

Author

Kissling, Esther, primary, Pozo, Francisco, additional, Martínez-Baz, Iván, additional, Buda, Silke, additional, Vilcu, Ana-Maria, additional, Domegan, Lisa, additional, Ateca, Clara Mazagatos, additional, Dijkstra, Frederika, additional, Latorre-Margalef, Neus, additional, Filipovićović, Sanja Kurečić, additional, Machado, Ausenda, additional, Lazar, Mihaela, additional, Buesa, Itziar Casado, additional, Dürrwald, Ralf, additional, Werf, Sylvie van der, additional, O'Donnell, Joan, additional, Dopido, Juan Antonio Linares, additional, Meijer, Adam, additional, Riess, Maximilian, additional, Vučina, Vesna Višekruna, additional, Rodrigues, Ana Paula, additional, Mihai, Maria Elena, additional, Castilla, Jesus, additional, Goerlitz, Luise, additional, Falchi, Alessandra, additional, Connell, Jeff, additional, Castrillejo, Daniel, additional, Hooiveld, Mariette, additional, Carnahan, AnnaSara, additional, Ilić, Maja, additional, Guiomar, Raquel, additional, Ivanciuc, Alina-Elena, additional, Maurel, Marine, additional, Omokanye, Ajibol, additional, and Valenciano, Marta, additional

Published
2022
Full Text
View/download PDF

16. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre analysis, I-MOVE-COVID-19 and ECDC networks, July to August 2021

Author

Kissling, Esther, Hooiveld, Mariëtte, Martínez-Baz, Iván, Mazagatos, Clara, William, Naoma, Vilcu, Ana-Maria, Kooijman, Marjolein N, Ilić, Maja, Domegan, Lisa, Machado, Ausenda, de Lusignan, Simon, Lazar, Mihaela, Meijer, Adam, Brytting, Mia, Casado, Itziar, Larrauri, Amparo, Murray, Josephine-L K, Behillil, Sylvie, de Gier, Brechje, Mlinarić, Ivan, O'Donnell, Joan, Rodrigues, Ana Paula, Tsang, Ruby, Timnea, Olivia, de Lange, Marit, Riess, Maximilian, Castilla, Jesús, Pozo Sanchez, Francisco, Hamilton, Mark, Falchi, Alessandra, Knol, Mirjam J, Kurečić Filipović, Sanja, Dunford, Linda, Guiomar, Raquel, Cogdale, Jade, Cherciu, Carmen, Jansen, Tessa, Enkirch, Theresa, Basile, Luca, Connell, Jeff, Gomez, Verónica, Sandonis-Martin, Virginia, Bacci, Sabrina, Rose, Angela Mc, Pastore Celentano, Lucia, Valenciano, Marta, I-MOVE-COVID-19, ECDC primary care study teams, Conde-San Román, Patricia, Casas Flecha, Inmaculada, Oliva Dominguez, Jesus Angel, Delgado-Sanz, Concepcion, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Institute of Health Carlos III, Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Croatian Institute of Public Health [Zagreb] (CIPH), Health Service Executive [Dublin] (HSE), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), University of Oxford, Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Public Health Agency of Sweden, Instituto de Salud Carlos III [Madrid] (ISC), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Biologie des ARN et virus influenza - RNA Biology of Influenza Virus (CNRS-UMR3569), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), University College Dublin [Dublin] (UCD), UK Health Security Agency [London] (UKHSA), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), I-MOVE-COVID-19 and ECDC primary care study team Katica Čusek Adamić, Ivana Ferenčak, Bernard Kaić, Mirjana Lana Kosanović Ličina, Danijela Lakošeljac, Ivana Mihin Huskić, Diana Nonković, Nick Andrews, Jamie Lopez Bernal, Joanna Ellis, Heather Whitaker, Thierry Blanchon, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Lois O'Connor, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Rianne van Gageldonk-Lafeber, Susan J Hahné, Hester E de Melker, Ewout B Fanoy, Stijn Raven, Marit Middeldorp, Irina Kislaya, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Amélia Soeiro, Maria Elena Mihai, Iulia Bistriceanu, Alina Ivanciuc, Diana Dintoi, Catalina Pascu, Adrian Jidovu, Debbie Sigerson, Diogo Fp Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Inmaculada Casas Flecha, Ana Martínez Mateo, Daniel Castrillejo, Eva María Martínez Ochoa, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Cristina Burgui, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Pasi Penttinen, Christiana Carstairs, University of St Andrews. School of Medicine, Unión Europea. Comisión Europea. H2020, and European Centre for Disease Prevention and Control

Subjects
Test-negative design, RM, Delta variant, COVID-19 Vaccines, Epidemiology, [SDV]Life Sciences [q-bio], Multicentre study, Influenza, Human/prevention & control, MESH: Primary Health Care, Europe/epidemiology, MESH: Influenza Vaccines, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Influenza, Human, Humans, MESH: COVID-19, MESH: SARS-CoV-2, COVID-19/epidemiology, Vaccine effectiveness, QR355, MESH: Humans, Primary Health Care, vaccine effectiveness, SARS-CoV-2, MESH: Influenza, Human, Vaccination, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, MESH: Vaccination, NIS, multicentre study, RM Therapeutics. Pharmacology, Europe, Influenza Vaccines, MESH: COVID-19 Vaccines, SARS-COV-2, vaccine efffectiveness, MESH: Europe, QR355 Virology
Abstract

Introduction In July and August 2021, the SARS-CoV-2 Delta variant dominated in Europe. Aim Using a multicentre test-negative study, we measured COVID-19 vaccine effectiveness (VE) against symptomatic infection. Methods Individuals with COVID-19 or acute respiratory symptoms at primary care/community level in 10 European countries were tested for SARS-CoV-2. We measured complete primary course overall VE by vaccine brand and by time since vaccination. Results Overall VE was 74% (95% CI: 69–79), 76% (95% CI: 71–80), 63% (95% CI: 48–75) and 63% (95% CI: 16–83) among those aged 30–44, 45–59, 60–74 and ≥ 75 years, respectively. VE among those aged 30–59 years was 78% (95% CI: 75–81), 66% (95% CI: 58–73), 91% (95% CI: 87–94) and 52% (95% CI: 40–61), for Comirnaty, Vaxzevria, Spikevax and COVID-19 Vaccine Janssen, respectively. VE among people 60 years and older was 67% (95% CI: 52–77), 65% (95% CI: 48–76) and 83% (95% CI: 64–92) for Comirnaty, Vaxzevria and Spikevax, respectively. Comirnaty VE among those aged 30–59 years was 87% (95% CI: 83–89) at 14–29 days and 65% (95% CI: 56–71%) at ≥ 90 days between vaccination and onset of symptoms. Conclusions VE against symptomatic infection with the SARS-CoV-2 Delta variant varied among brands, ranging from 52% to 91%. While some waning of the vaccine effect may be present (sample size limited this analysis to only Comirnaty), protection was 65% at 90 days or more between vaccination and onset.

Published
2022
Full Text
View/download PDF

17. Influenza vaccine effectiveness against influenza A subtypes in Europe: Results from the 2021–2022 I‐MOVE primary care multicentre study

Author

Kissling, Esther, Pozo, Francisco, Martínez‐Baz, Iván, Buda, Silke, Vilcu, Ana‐Maria, Domegan, Lisa, Mazagatos, Clara, Dijkstra, Frederika, Latorre‐Margalef, Neus, Kurečić Filipović, Sanja, Machado, Ausenda, Lazar, Mihaela, Casado, Itziar, Dürrwald, Ralf, van der Werf, Sylvie, O'Donnell, Joan, Linares Dopido, Juan Antonio, Meijer, Adam, Riess, Maximilian, Višekruna Vučina, Vesna, Rodrigues, Ana Paula, Mihai, Maria Elena, Castilla, Jesús, Goerlitz, Luise, Falchi, Alessandra, Connell, Jeff, Castrillejo, Daniel, Hooiveld, Mariette, Carnahan, Annasara, Ilić, Maja, Guiomar, Raquel, Ivanciuc, Alina, Maurel, Marine, Omokanye, Ajibola, Valenciano, Marta, I‐MOVE study team, European Centre for Disease Prevention and Control, EpiConcept [Paris], Institute of Health Carlos III, CIBER de Epidemiología y Salud Pública (CIBERESP), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), National Institute for Public Health and the Environment [Bilthoven] (RIVM), University of Kalmar, Croatian Institute of Public Health [Zagreb] (CIPH), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP)-Université Paris Cité (UPCité), Dirección General de Salud Pública, Public Health Agency of Sweden, Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Cantacuzino National Medico-Military Institute for Research Development [Bucharest], Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, University College Dublin [Dublin] (UCD), School of Social Sciences. Campus de Melilla. Univeristy of Granada, Netherlands Institute for Health Services Research [Utrecht] (NIVEL), European Centre for Disease Prevention and Control [Stockholm, Sweden] (ECDC), and tudy teams are very grateful to all patients, general practitioners, paediatricians, laboratory teams, and regional epidemiologists who have contributed to the studies. Participating laboratories submitted their sequences to GISAID (www.gisaid.org) for easy sharing with the central laboratory in Madrid. We would like to acknowledge Mia Brytting, who sadly passed away before publication. She is deeply missed.

Subjects
Pulmonary and Respiratory Medicine, Male, Adult, Adolescent, Epidemiology, [SDV]Life Sciences [q-bio], Vaccine Efficacy, Multicentre study, Young Adult, Influenza A Virus, H1N1 Subtype, Influenza, Human, Humans, Europe, influenza, influenza vaccine, multicentre study, vaccine effectiveness, Child, Aged, Vaccine effectiveness, Primary Health Care, Influenza vaccine, Influenza A Virus, H3N2 Subtype, Vaccination, Public Health, Environmental and Occupational Health, Infant, Newborn, Infant, Middle Aged, vaccine effectiveness, multicentre study, Influenza, Europe, Infectious Diseases, Influenza Vaccines, Case-Control Studies, Child, Preschool, Female, influenza vaccine, influenza
Abstract

Background: In 2021-2022, influenza A viruses dominated in Europe. The I-MOVE primary care network conducted a multicentre test-negative study to measure influenza vaccine effectiveness (VE). Methods: Primary care practitioners collected information on patients presenting with acute respiratory infection. Cases were influenza A(H3N2) or A(H1N1)pdm09 RT-PCR positive, and controls were influenza virus negative. We calculated VE using logistic regression, adjusting for study site, age, sex, onset date, and presence of chronic conditions. Results: Between week 40 2021 and week 20 2022, we included over 11 000 patients of whom 253 and 1595 were positive for influenza A(H1N1)pdm09 and A(H3N2), respectively. Overall VE against influenza A(H1N1)pdm09 was 75% (95% CI: 43-89) and 81% (95% CI: 45-93) among those aged 15-64 years. Overall VE against influenza A(H3N2) was 29% (95% CI: 12-42) and 25% (95% CI: -41 to 61), 33% (95% CI: 14-49), and 26% (95% CI: -22 to 55) among those aged 0-14, 15-64, and over 65 years, respectively. The A(H3N2) VE among the influenza vaccination target group was 20% (95% CI: -6 to 39). All 53 sequenced A(H1N1)pdm09 viruses belonged to clade 6B.1A.5a.1. Among 410 sequenced influenza A(H3N2) viruses, all but eight belonged to clade 3C.2a1b.2a.2. Discussion: Despite antigenic mismatch between vaccine and circulating strains for influenza A(H3N2) and A(H1N1)pdm09, 2021-2022 VE estimates against circulating influenza A(H1N1)pdm09 were the highest within the I-MOVE network since the 2009 influenza pandemic. VE against A(H3N2) was lower than A(H1N1)pdm09, but at least one in five individuals vaccinated against influenza were protected against presentation to primary care with laboratory-confirmed influenza. This project has received funding from the European Centre for Disease Prevention and Control with in the framework contract ECDC/2018/029. Sí

Published
2022
Full Text
View/download PDF

18. High prevalence of hepatitis delta virus among persons who inject drugs, Vietnam

Author

Hall, Naomi, Thuy, Linh Nguyen, Diem, Trinh Do Thi, Waters, Allison, Dunford, Linda, Connell, Jeff, Carr, Michael, Hall, William, and Thi, Lan Anh Nguyen

Subjects
Distribution, Physiological aspects, Research, Company distribution practices, Prevalence studies (Epidemiology) -- Research, Hepatitis viruses -- Physiological aspects -- Distribution -- Research
Abstract

To the Editor: Hepatitis delta virus (HDV) is a small RNA virus that infects and persists only in persons whose samples test positive for hepatitis B surface antigen (HB-sAg) (1). [...]

Published
2015

20. Vaccine effectiveness against symptomatic SARS-CoV-2 infection in adults aged 65 years and older in primary care : I-MOVE-COVID-19 project, Europe, December 2020 to May 2021

Author

Kissling, Esther, Hooiveld, Mariette, Sandonis Martín, Virginia, Martínez-Baz, Iván, William, Naoma, Vilcu, Ana-Maria, Mazagatos, Clara, Domegan, Lisa, de Lusignan, Simon, Meijer, Adam, Machado, Ausenda, Brytting, Mia, Casado, Itziar, Murray, Josephine-L K., Belhillil, Sylvie, Larrauri, Amparo, O’Donnell, Joan, Tsang, Ruby, de Lange, Marit, Rodrigues, Ana Paula, Riess, Maximilian, Castilla, Jesús, Hamilton, Mark, Falchi, Alessandra, Pozo, Francisco, Dunford, Linda, Cogdale, Jade, Jansen, Tessa, Guiomar, Raquel, Enkirch, Theresa, Burgui, Cristina, Sigerson, Debbie, Blanchon, Thierry, Martínez Ochoa, Eva María, Connell, Jeff, Ellis, Joanna, van Gageldonk-Lafeber, Rianne, Kislaya, Irina, Rose, Angela MC, Valenciano, Marta, Andrews, Nick, Lopez Bernal, Jamie, Whitaker, Heather, Guerrisi, Caroline, Launay, Titouan, Masse, Shirley, van der Werf, Sylvie, Enouf, Vincent, Cuddihy, John, McKenna, Adele, Joyce, Michael, de Gascun, Cillian, Moran, Joanne, Miqueleiz, Ana, Navascués, Ana, Trobajo-Sanmartín, Camino, Ezpeleta, Carmen, Moreno, Paula López, Gorricho, Javier, Ardanaz, Eva, Baigorria, Fernando, Barricarte, Aurelio, de la Cruz, Enrique, Egüés, Nerea, García Cenoz, Manuel, Guevara, Marcela, Moreno-Iribas, Conchi, Sayón, Carmen, Gomez, Verónica, Nunes, Baltazar, Roquete, Rita, Silva, Adriana, Melo, Aryse, Costa, Inês, Verdasca, Nuno, Conde, Patrícia, Marques, Diogo FP, Molesworth, Anna, Quinn, Leanne, Leyton, Miranda, Campbell, Selin, Thoulass, Janine, McMenamin, Jim, Mateo, Ana Martínez, Basile, Luca, Castrillejo, Daniel, Quiñones Rubio, Carmen, Delgado-Sanz, Concepción, Oliva., Jesús, University of St Andrews. School of Medicine, team, I-MOVE-COVID-19 primary care study, above), I-MOVE-COVID-19 primary care study team (in addition to authors, EpiConcept [Paris], Netherlands Institute for Health Services Research [Utrecht] (NIVEL), Instituto de Salud Carlos III [Madrid] (ISC), Navarra Institute for Health Research / Instituto de Investigación Sanitaria de Navarra (IdiSNA), Universidad Pública de Navarra [Espagne] = Public University of Navarra (UPNA)-Universidad de Navarra [Pamplona] (UNAV)-Clínica Universidad de Navarra [Pamplona], CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Scotland [Glasgow], Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), Health Service Executive [Dublin] (HSE), University of Oxford, National Institute for Public Health and the Environment [Bilthoven] (RIVM), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), Public Health Agency of Sweden, Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), Università di Corsica Pasquale Paoli [Université de Corse Pascal Paoli], Partenaires INRAE, Institut National de la Santé et de la Recherche Médicale (INSERM), University College Dublin [Dublin] (UCD), Public Health England [London], Dirección General de Salud Pública, This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673., European Project: 101003673,H2020-SC1-PHE-CORONAVIRUS-2020,I-MOVE-COVID-19(2020), and Unión Europea. Comisión Europea. H2020

Subjects
Infecções Respiratórias, Adult, Test-negative design, 2019-20 coronavirus outbreak, Pediatrics, medicine.medical_specialty, RM, COVID-19 Vaccines, Coronavirus disease 2019 (COVID-19), Epidemiology, Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), [SDV]Life Sciences [q-bio], Primary health care, Primary care, 030204 cardiovascular system & hematology, Multicentre study, 03 medical and health sciences, Elderly, 0302 clinical medicine, SDG 3 - Good Health and Well-being, RA0421, RA0421 Public health. Hygiene. Preventive Medicine, Virology, Medicine, Humans, 030212 general & internal medicine, Aged, Vaccine effectiveness, QR355, vaccine effectiveness, Primary Health Care, business.industry, SARS-CoV-2, Efetividade da vacina contra COVID-19, test-negative design, Public Health, Environmental and Occupational Health, COVID-19, 3rd-DAS, NIS, Estados de Saúde e de Doença, multicentre study, 3. Good health, RM Therapeutics. Pharmacology, Vaccination, Europe, Determinantes da Saúde e da Doença, business, QR355 Virology, Rapid Communication
Abstract

I-MOVE-COVID-19 primary care study team (in addition to authors above): Nick Andrews, Jamie Lopez Bernal, Heather Whitaker, Caroline Guerrisi, Titouan Launay, Shirley Masse, Sylvie van der Werf, Vincent Enouf, John Cuddihy, Adele McKenna, Michael Joyce, Cillian de Gascun, Joanne Moran, Ana Miqueleiz, Ana Navascués, Camino Trobajo-Sanmartín, Carmen Ezpeleta, Paula López Moreno, Javier Gorricho, Eva Ardanaz, Fernando Baigorria, Aurelio Barricarte, Enrique de la Cruz, Nerea Egüés, Manuel García Cenoz, Marcela Guevara, Conchi Moreno-Iribas, Carmen Sayón, Verónica Gomez, Baltazar Nunes, Rita Roquete, Adriana Silva, Aryse Melo, Inês Costa, Nuno Verdasca, Patrícia Conde, Diogo FP Marques, Anna Molesworth, Leanne Quinn, Miranda Leyton, Selin Campbell, Janine Thoulass, Jim McMenamin, Ana Martínez Mateo, Luca Basile, Daniel Castrillejo, Carmen Quiñones Rubio, Concepción Delgado-Sanz, Jesús Oliva. The I-MOVE-COVID-19 network collates epidemiological and clinical information on patients with coronavirus disease (COVID-19), including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) virological characterisation in 11 European countries [1]. One component of I-MOVE-COVID-19 is the multicentre vaccine effectiveness (VE) study at primary care/outpatient level in nine European study sites in eight countries. We measured overall and product-specific COVID-19 VE against symptomatic SARS-CoV-2 infection among those aged 65 years and older. We also measured VE by time since vaccination. This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 101003673. info:eu-repo/semantics/publishedVersion

Published
2021
Full Text
View/download PDF

21. Underreporting of viral encephalitis and viral meningitis, Ireland, 2005-2008

Author

Kelly, Tara A., O'Lorcain, Piaras, Moran, Joanne, Garvey, Patricia, McKeown, Paul, Connell, Jeff, and Cotter, Suzanne

Subjects
Statistics, Research, Viral meningitis -- Statistics, Sentinel surveillance -- Research, Viral encephalitis -- Statistics, Encephalitis, Viral -- Statistics, Sentinel health events -- Research
Abstract

Encephalitis and meningitis are serious inflammatory diseases of the brain that require hospitalization for many patients and are a substantial cause of illness. Although the etiologic agent is not identified [...]

Published
2013
Full Text
View/download PDF

22. Effectiveness of complete primary vaccination against COVID-19 at primary care and community level during predominant Delta circulation in Europe: multicentre study analysis by age-group, vaccine brand and time since vaccination, I-MOVE-COVID-19 and ECDC networks, July–August 2021

Author

Kissling, Esther, primary, Hooiveld, Mariëtte, additional, Martínez-Baz, Iván, additional, Mazagatos, Clara, additional, William, Naoma, additional, Vilcu, Ana-Maria, additional, Kooijman, Marjolein N., additional, Ilić, Maja, additional, Domegan, Lisa, additional, Machado, Ausenda, additional, de Lusignan, Simon, additional, Lazar, Mihaela, additional, Meijer, Adam, additional, Brytting, Mia, additional, Casado, Itziar, additional, Larrauri, Amparo, additional, Murray, Josephine-L K., additional, Behillil, Sylvie, additional, de Gier, Brechje, additional, Mlinarić, Ivan, additional, O'Donnell, Joan, additional, Rodrigues, Ana Paula, additional, Tsang, Ruby, additional, Timnea, Olivia, additional, de Lange, Marit, additional, Riess, Maximilian, additional, Castilla, Jesús, additional, Pozo, Francisco, additional, Hamilton, Mark, additional, Falchi, Alessandra, additional, Knol, Mirjam J., additional, Filipović, Sanja Kurečić, additional, Dunford, Linda, additional, Guiomar, Raquel, additional, Cogdale, Jade, additional, Cherciu, Carmen, additional, Jansen, Tessa, additional, Enkirch, Theresa, additional, Basile, Luca, additional, Connell, Jeff, additional, Gomez, Verónica, additional, Martín, Virginia Sandonis, additional, Bacci, Sabrina, additional, Rose, Angela MC, additional, Celentano, Lucia Pastore, additional, and Valenciano, Marta, additional

Published
2021
Full Text
View/download PDF

23. The Study to Investigate COVID-19 Infection in People Living in Ireland (SCOPI): A seroprevalence study, June to July 2020

Author

Heavey, Laura, primary, Garvey, Patricia, additional, Colgan, Aoife M, additional, Thornton, Lelia, additional, Connell, Jeff, additional, Roux, Thomas, additional, Hunt, Meadhbh, additional, O'Callaghan, Fiona, additional, Culkin, Fiona, additional, Keogan, Mary, additional, O'Connor, Nuala, additional, O'Sullivan, Margaret B, additional, O’Sullivan, Siobhán, additional, Tait, Michele, additional, De Gascun, Cillian F, additional, and Igoe, Derval, additional

Published
2021
Full Text
View/download PDF

24. Deaths associated with human adenovirus-14p1 infections, Europe, 2009-2010

Author

Carr, Michael J., Kajon, Adriana E., Lu, Xiaoyan, Dunford, Linda, O'Reilly, Paul, Holder, Paul, De Gascun, Cillian F., Coughlan, Suzie, Connell, Jeff, Erdman, Dean D., and Hall, William W.

Subjects
Development and progression, Health aspects, Online health care service, Continuing medical education -- Health aspects, Online health care information services -- Health aspects, Adenoviruses -- Health aspects
Abstract

Human adenovirus (HAdV) serotype 14 is rarely identified. However, an emerging variant, termed HAdV-14p1, recently has been described in the United States in association with outbreaks of acute respiratory disease [...]

Published
2011
Full Text
View/download PDF

27. Mapping of serological testing and SARS-CoV-2 seroprevalence studies performed in 20 European countries, March-June 2020

Author

Bubba, Laura, primary, Simmonds, Peter, additional, Fischer, Thea K, additional, Harvala, Heli, additional, Weseslindtner, Lukas, additional, Spuchhammer-Stockl, Elisabeth, additional, Marijke, Reynders, additional, Dedeic Ljubovic, Amela, additional, Aleksandrova, Dora, additional, Tabain, Irena, additional, Rainetova, Petra, additional, Jirincova, Helena, additional, Bang, Didi, additional, Fickenscher, Helmut, additional, Krumbholz, Andi, additional, Panning, Marcus, additional, Huzly, Daniela, additional, Eis-Hübinger, Anna M, additional, Papa, Anna, additional, Sourvinos, George, additional, Zafiropoulos, Alexandros, additional, Ásgeirsson, Asgeir Erlendur, additional, Connell, Jeff, additional, Percivalle, Elena, additional, Cassaniti, Irene, additional, Karen, Couderé, additional, Lind, Andreas, additional, Nordbo, Svein Arne, additional, de Sao Jose Nascimento, Maria, additional, Mesquita, Joao Rodrigo, additional, Brito, Maria, additional, Guiomar, Raquel, additional, Rodrigues, Ana Paula, additional, Fonseca e Silva, Daniela, additional, Abreu, Ana, additional, Dessa, Paulo, additional, Popescu, Corneliu Petru, additional, Berginc, Natasa, additional, ProsencTrilar, Katarina, additional, Poljak, Mario, additional, Rabella, Nuria, additional, Esperalba, Juliana, additional, Perez-Olmeda, Mayte, additional, Fernández-García, Aurora, additional, Bogdanovic, Gordana, additional, Muschiol, Sandra, additional, Bohn Christiansen, Claus, additional, Can Sarınoglu, Rabia, additional, Karahasan Yagci, Aysegul, additional, Zeytinoglu, Aysin, additional, Soylu, Mehmet, additional, Sener, Burcin, additional, and Alp, Alpaslan, additional

Published
2021
Full Text
View/download PDF

28. Specialist laboratory networks as preparedness and response tool - the Emerging Viral Diseases-Expert Laboratory Network and the Chikungunya outbreak, Thailand, 2019

Author

Venturi, Giulietta, Aberle, Stephan W, Avšič-Županc, Tatjana, Barzon, Luisa, Batejat, Christoph, Burdino, Elisa, Carletti, Fabrizio, Charrel, Rémi, Christova, Iva, Connell, Jeff, Corman, Victor Max, Emmanouil, Mary, Jääskeläinen, Anne J, Kurolt, Ivan, Lustig, Yaniv, Martinez, Miguel J, Koopmans, Marion, Nagy, Orsolya, Nguyen, Trung, Papa, Anna, Pérez-Ruiz, Mercedes, Pfeffer, Martin, Protic, Jelena, Reimerink, Johan, Rossini, Giada, Sánchez-Seco Fariñas, María Paz, Schmidt-Chanasit, Jonas, Söderholm, Sandra, Sudre, Bertrand, Van Esbroeck, Marjan, and Reusken, Chantal B

Subjects
EVD-LabNet, chikungunya, lab surveillance, Thailand, lab preparedness and response, travel
Published
2020

34. Mycoplasma pneumoniae infections, 11 countries in Europe and Israel, 2011 to 2016

Author

Beeton, Michael L., Zhang, Xu-Sheng, Uldum, Soren A., Bebear, Cecile, Dumke, Roger, Gullsby, Karolina, Ieven, Margaretha, Loens, Katherine, Nir-Paz, Ran, Pereyre, Sabine, Spiller, O. Brad, Chalker, Victoria J., Bossuyt, Nathalie, Lagrou, Katrien, Mitis, George, Koliou, Maria, Havlickova, Martina, Kyncl, Jan, Emborg, Hanne-Dorthe, Voldstedlund, Marianne, MacKenzie, Colin Rae, Maltezou, Helena C., Georgakopoulou, Theano, Petridou, Evangelina, Banou, Kirkira, Balla, Eszter, Connell, Jeff, Yandle, Zoe, Moran, Joanne, Burns, Karen, Michael-Gayego, Ayelet, Moses, Allon E., Fenech, Tanya Melillo, Anestad, Gabriel, Blystad, Hans, Vestrheim, Didrik F., Froes, Filipe, Kese, Darja, Socan, Maja, Cano Portero, Rosa, Santos Sanz, Sara, Suarez Rodriguez, Berta, Ternhag, Anders, Giske, Christian, Wisell, Karin Tegmark, Marques, Diogo Pereira, Reynolds, Arlene, McMenamin, Jim, ESCMID Study Grp Mycoplasma Ch, Cardiff Metropolitan University, Public Health England, Statens seruminstitut, Technische Universität Dresden = Dresden University of Technology (TU Dresden), Uppsala University, Antwerp University Hospital [Edegem] (UZA), Hadassah Hebrew University Medical Center, Partenaires INRAE, USC IHMC - Infections humaines à mycoplasmes et à chlamydiae, Institut National de la Recherche Agronomique (INRA), and Cardiff University

Subjects
0301 basic medicine, Mycoplasma pneumoniae, Epidemiology, [SDV]Life Sciences [q-bio], Infektionsmedicin, VARIANTS, medicine.disease_cause, 0302 clinical medicine, Surveys and Questionnaires, diagnostics, Medicine, 030212 general & internal medicine, REAL-TIME PCR, Israel, Diagnostics, Surveillance, Electronic Mail, MACROLIDE RESISTANCE, Mycoplasma pneumoniae Infections, ABSENCE, 3. Good health, Anti-Bacterial Agents, Community-Acquired Infections, Europe, Infectious Diseases, surveillance, GERMANY, epidemiology, Female, Macrolides, Life Sciences & Biomedicine, Nucleic Acid Amplification Techniques, medicine.medical_specialty, Infectious Medicine, 030106 microbiology, FRANCE, Microbiology, 03 medical and health sciences, Age Distribution, EPIDEMIC, Virology, Drug Resistance, Bacterial, Pneumonia, Mycoplasma, Humans, Epidemics, Retrospective Studies, Science & Technology, business.industry, Research, STRAINS, Public Health, Environmental and Occupational Health, medicine.disease, Pneumonia, ANTIBODIES, Human medicine, business
Abstract

Mycoplasma pneumoniae is a major cause of respiratory infection in humans and macrolide antibiotics, such as azithromycin, are used as the first-line of treatment in many countries. The bacterium is transmitted from person-to-person by respiratory droplets with the incubation period ranging from 4 days to 3 weeks [1]. Because of M. pneumoniae’s intrinsic resistance to many antibiotics, including all cell wall inhibitors, macrolide antibiotics such as azithromycin and clarithromycin are the drug of choice for treatment. In cases of suspected infection in immunocompromised individuals, bactericidal fluoroquinolones may be considered. Tetracyclines are an alternative for treatment of adults with possible macrolide-resistant M. pneumoniae infections. Prudent use of antibiotics has been urged for all cases of M. pneumoniae infection because of worldwide reports of macrolide resistance, which have been reported as ranging from 0.2% in Sweden to more than 90% in China [2-5].\ud \ud M. pneumoniae infections show seasonal variation. In temperate climates, the number of infections peak during the latter months of the years, with epidemic periods every 4 to 7 years on average [6-8]. The most recent survey in 2012 by Lenglet et al indicated that some countries in the European Union and European Economic Area experienced an increase in M. pneumoniae cases in 2011 whereas others did not, indicating that a universal geographic increase had not occurred [5]. Little is understood about the transmission of M. pneumoniae within populations and several factors have been postulated to account for transmission dynamics, including the immunity level of the population, the bacterial population based on the P1 adhesin type, the age and extent of mixing of children in educational settings.\ud \ud Methodologies for detection of M. pneumoniae include nucleic acid amplification tests (NAAT), serology and culture with varying sensitivities and specificities. There is no international standard material for quality control detection in assays, although external quality control schema exist for some methodologies (NAAT). There are no internationally defined guidelines on the requirements for surveillance of M. pneumoniae, macrolide resistance testing and surveillance, reference system structure, routine testing and bacterial strain discrimination. However, a few countries such as France and the United States (US) have surveillance within specific regions and national surveillance is seen in countries such as Denmark [9] and Japan, the latter of which has maintained an active surveillance system for this pathogen for some time [10]. Overall, laboratory confirmed cases and surveillance data regarding the number of cases and reported cases of macrolide resistance are likely to be underestimated. This is further confounded because an undefined proportion of patients will have mild disease or may be carriers within community settings, without active testing to confirm the infection. Further underestimation is likely to occur from patients receiving empirical treatment in the absence of laboratory-confirmed infection with M. pneumoniae.

Published
2020
Full Text
View/download PDF

35. Low 2018/19 vaccine effectiveness against influenza A(H3N2) among 15–64-year-olds in Europe: exploration by birth cohort

Author

Kissling, Esther, Pozo, Francisco, Buda, Silke, Vilcu, Ana-Maria, Gherasim, Alin, Brytting, Mia, Domegan, Lisa, Gomez, Veronica, Meijer, Adam, Lazar, Mihaela, Vucina, Vesna Visekruna, Duerrwald, Ralf, van der Werf, Sylvie, Larrauri, Amparo, Enkirch, Theresa, O'Donnell, Joan, Guiomar, Raquel, Hooiveld, Mariette, Petrovic, Goranka, Stoian, Elena, Penttinen, Pasi, Valenciano, Marta, Preuss, Ute, Tolksdorf, Kristin, Biere, Barbara, Smallfield, Maria, Wedde, Marianne, Falchi, Alessandra, Masse, Shirley, Villechenaud, Natacha, Souty, Cecile, Blanchon, Thierry, Launay, Titouan, Enouf, Vincent, Behillil, Sylvie, Lina, Bruno, Valette, Martine, Mazagatos, Clara, Casas, Inmaculada, Garcia Comas, Luis, Insua Marisquerena, Maria Esther, Carlos Galan, Juan, Castilla, Jesus, Garcia Cenoz, Manuel, Navascues, Ana, Quinones Rubio, Carmen, Ibanez Perez, Ana Carmen, Martinez Ochoa, Eva, Blasco, Miriam, Gimenez Duran, Jaume, Maria Vanrell, Juana, Reina, Jordi, Castrillejo, Daniel, Wiman, Asa, Hunt, Meadhbh, Joyce, Michael, Levis, Olga, Collins, Claire, Dunford, Linda, Bennett, Charlene, Moran, Joanne, Tuite, Grainne, Connell, Jeff, de Gascun, Cillian, Rodrigues, Ana Paula, Machado, Ausenda, Nunes, Baltazar, Kislaya, Irina, Costa, Ines, Conde, Patricia, Cristovao, Paula, Pechirra, Pedro, Borges, Vitor, Bagheri, Mariam, van den Brink, Sharon, Dijkstra, Frederika, Goderski, Gabriel, van der Hoek, Wim, de Lange, Marit, Marzec, Ton, Overduin, Pieter, Reukers, Daphne, Teirlinck, Anne, Wijsman, Lisa, Donker, Ge, Mihai, Maria Elena, Cherciu, Carmen Maria, Alexandrescu, Viorel, Kaic, Bernard, Filipovic, Sanja Kurecic, Novosel, Iva Pem, Makaric, Zvjezdana Lovric, Zajec, Martina, Drazenovic, Vladimir, Moren, Alain, I-MOVE Primary Care Study Team, EpiConcept [Paris], Instituto de Salud Carlos III [Madrid] (ISC), Robert Koch Institute [Berlin] (RKI), Institut Pierre Louis d'Epidémiologie et de Santé Publique (iPLESP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU), CIBER de Epidemiología y Salud Pública (CIBERESP), Public Health Agency of Sweden, Health Protection Surveillance Centre (HPSC), Instituto Nacional de Saùde Dr Ricardo Jorge [Portugal] (INSA), National Institute for Public Health and the Environment [Bilthoven] (RIVM), Cantacuzino Institute [Romania], Réseau International des Instituts Pasteur (RIIP), Génétique Moléculaire des Virus à ARN - Molecular Genetics of RNA Viruses (GMV-ARN (UMR_3569 / U-Pasteur_2)), Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)-Université Paris Cité (UPCité), Centre National de Référence des virus des infections respiratoires (dont la grippe) - National Reference Center Virus Influenzae [Paris] (CNR - laboratoire coordonnateur), Institut Pasteur [Paris] (IP), and Netherlands Institute for Health Services Research [Utrecht] (NIVEL)

Subjects
vacunas de la gripe, Male, 0301 basic medicine, potencia vacunal, Epidemiology, [SDV]Life Sciences [q-bio], humanos, Gripe, adolescente, Hemagglutinin Glycoproteins, Influenza Virus, virus de la influenza A, 0302 clinical medicine, infecciones del tracto respiratorio, memoria inmunológica, vigilancia centinela, Determinantes de Saúde e Doença, Medicine, 030212 general & internal medicine, Respiratory Tract Infections, mediana edad, Vaccine effectiveness, anciano, birth cohorts, Birth cohorts, Estado de Saúde e Doença, resultado del tratamiento, Vaccination, Age Factors, Imprinting, adulto, Middle Aged, multicentre study, Europe, Treatment Outcome, Influenza A virus, Época 2018-2019, Influenza Vaccines, Population Surveillance, Female, Seasons, imprinting, influenza, Birth cohort, A(H3N2), Adult, Adolescent, Primary care, Multicentre study, vacunación, 03 medical and health sciences, vigilancia de la población, Virology, Influenza, Human, Humans, ddc:610, Vacina Antigripal, EuroEVA, Vaccine Potency, Aged, vaccine effectiveness, business.industry, Influenza A Virus, H3N2 Subtype, Research, Efetividade, Public Health, Environmental and Occupational Health, Influenza a, Influenza, estaciones (meteorología), 030104 developmental biology, influenza vaccination, test negative case control, vaccine effectiveness, 610 Medizin und Gesundheit, business, Immunologic Memory, Sentinel Surveillance, Demography
Abstract

Introduction Influenza A(H3N2) clades 3C.2a and 3C.3a co-circulated in Europe in 2018/19. Immunological imprinting by first childhood influenza infection may induce future birth cohort differences in vaccine effectiveness (VE). Aim The I-MOVE multicentre primary care test-negative study assessed 2018/19 influenza A(H3N2) VE by age and genetic subgroups to explore VE by birth cohort. Methods We measured VE against influenza A(H3N2) and (sub)clades. We stratified VE by usual age groups (0–14, 15–64, ≥ 65-years). To assess the imprint-regulated effect of vaccine (I-REV) hypothesis, we further stratified the middle-aged group, notably including 32–54-year-olds (1964–86) sharing potential childhood imprinting to serine at haemagglutinin position 159. Results Influenza A(H3N2) VE among all ages was −1% (95% confidence interval (CI): −24 to 18) and 46% (95% CI: 8–68), −26% (95% CI: −66 to 4) and 20% (95% CI: −20 to 46) among 0–14, 15–64 and ≥ 65-year-olds, respectively. Among 15–64-year-olds, VE against clades 3C.2a1b and 3C.3a was 15% (95% CI: −34 to 50) and −74% (95% CI: −259 to 16), respectively. VE was −18% (95% CI: −140 to 41), −53% (95% CI: −131 to −2) and −12% (95% CI: −74 to 28) among 15–31-year-olds (1987–2003), 32–54-year-olds (1964–86) and 55–64-year-olds (1954–63), respectively. Discussion The lowest 2018/19 influenza A(H3N2) VE was against clade 3C.3a and among those born 1964–86, corresponding to the I-REV hypothesis. The low influenza A(H3N2) VE in 15–64-year-olds and the public health impact of the I-REV hypothesis warrant further study.

Published
2019
Full Text
View/download PDF

37. Dietitian in condition: whether she's acting, modeling or counseling clients, Stephanie Logan's fit body is her first calling card

Author

Connell, Jeff O.

Subjects
Practice, Management, Beliefs, opinions and attitudes, Methods, Training, Company business management, Personal trainers -- Training -- Practice -- Beliefs, opinions and attitudes, Fashion models -- Training -- Practice -- Beliefs, opinions and attitudes, Women's fitness -- Management -- Methods, Actors -- Training -- Practice -- Beliefs, opinions and attitudes, Actresses -- Training -- Practice -- Beliefs, opinions and attitudes
Abstract

A grayish Thursday in normally sunny L.A. nonetheless offers a clear view of the fashionably eclectic life of Stephanie Logan. Earlier that morning, the lifelong sports and fitness buff had [...]

Published
2002

40. Erratum to “Predominance of influenza A(H3N2) virus genetic subclade 3C.2a1 during an early 2016/17 influenza season in Europe – Contribution of surveillance data from World Health Organization (WHO) European region to the WHO vaccine composition consultation for northern hemisphere 2017/18” [Vaccine 35 (2017) 4828–4835]

Author

Melidou, Angeliki, primary, Broberg, Eeva, additional, Adlhoch, Cornelia, additional, Snacken, René, additional, Penttinen, Pasi, additional, Pereyaslov, Dmitriy, additional, Brown, Caroline, additional, Redlberger-Fritz, Monika, additional, Popow-Kraupp, Therese, additional, Thomas, Isabelle, additional, Barbezange, Cyril, additional, Bossuyt, Nathalie, additional, Jirincova, Helena, additional, Nagy, Alexander, additional, Trebbien, Ramona, additional, Fischer, Thea K., additional, Ikonen, Niina, additional, Haveri, Anu, additional, Lyytikäinen, Outi, additional, Murtopuro, Satu, additional, Behillil, Sylvie, additional, Enouf, Vincent, additional, van der Werf, Sylvie, additional, Falchi, Alessandra, additional, Valette, Martine, additional, Lina, Bruno, additional, Schweiger, Brunhilde, additional, Biere, Barbara, additional, Duwe, Susanne, additional, Wedde, Marianne, additional, Buda, Silke, additional, Mentis, Andreas, additional, Kossyvakis, Athanasios, additional, Pogka, Vasiliki, additional, Papa-Konidari, Anna, additional, Melidou, Angeliki, additional, Gioula, Georgia, additional, Exindari, Maria, additional, Dunford, Linda, additional, Connell, Jeff, additional, Tuite, Grainne, additional, Duffy, Margaret, additional, Moran, Joanne, additional, Hogg, Bridget, additional, Waters, Allison, additional, de Gascun, Cillian, additional, Domegan, Lisa, additional, O'Donnell, Joan, additional, Joyce, Michael, additional, Rita Castrucci, Maria, additional, Puzelli, Simona, additional, Rizzo, Caterina, additional, Bella, Antonino, additional, Maraglino, Francesco, additional, Otorbaeva, Dinagul, additional, Saparova, Gulbarchyn, additional, Zamjatina, Natalija, additional, Pakarna, Gatis, additional, Nikiforova, Raina, additional, Mossong, Joël, additional, Opp, Matthias, additional, Meijer, Adam, additional, Overduin, Pieter, additional, de Lange, Marit, additional, Teirlinck, Anne, additional, Rimmelzwaan, Guus, additional, van Beek, Ruud, additional, Koopmans, Marion, additional, Donker, Gé, additional, Hungnes, Olav, additional, Bragstad, Karoline, additional, Guiomar, Raquel, additional, Pechirra, Pedro, additional, Cristóvão, Paula, additional, Costa, Inês, additional, Conde, Patricia, additional, Paula Rodrigues, Ana, additional, Elena Ivanciuc, Alina, additional, Burtseva, Elena, additional, Kirillova, Elena, additional, Mukasheva, Evgeniya, additional, Tichá, Elena, additional, Prosenc, Katarina, additional, Berginc, Nataša, additional, Pozo, Francisco, additional, Casas, Inmaculada, additional, Larrauri, Amparo, additional, Oliva, Jesús, additional, Delgado, Concha, additional, Ortiz de Lejarazu Leonardo, Raúl, additional, Brytting, Mia, additional, Wiman, Åsa, additional, Cordey, Samuel, additional, Rita Goncalves, Ana, additional, Perisa, Damir, additional, Born, Rita, additional, Ellis, Joanna, additional, Galiano, Monica, additional, Thompson, Catherine, additional, Zambon, Maria, additional, Pebody, Richard, additional, Gunson, Rory, additional, Reynolds, Arlene, additional, McMenamin, Jim, additional, McCaughey, Conall, additional, and Kearns, Cathriona, additional

Published
2018
Full Text
View/download PDF

44. An ongoing measles outbreak linked to a suspected imported case, Ireland, April to June 2016

Author

Barrett, Peter, primary, Chaintarli, Katerina, additional, Ryan, Fiona, additional, Cotter, Suzanne, additional, Cronin, Anthony, additional, Carlton, Louise, additional, MacSweeney, Mary, additional, McDonnell, Mairead, additional, Connell, Jeff, additional, Fitzgerald, Rose, additional, Hamilton, Douglas, additional, Ward, Mary, additional, Glynn, Ronan, additional, and Migone, Chantal, additional

Published
2016
Full Text
View/download PDF

46. Predominant Inflammatory and Th1 biased cytokine secretion pre- and post- kidney transplantation

Author

BENNETT, Charlene, WATERS, Allison, MORAN, Julie, CONNELL, Jeff, HALL, William, and HASSAN, Jaythoon

Subjects
Kidney transplant,allograft rejection,cytokines,Th1 bias
Abstract

A key goal in post-transplant monitoring is the diagnostic detection of harmful processes in the allograft early which can be easily and non-invasively assessed. Cytokines are crucial mediators involved in immune responses leading to rejection. It is known that episodes of viral infections and acute rejection can cause an increase in pro-inflammatory cytokines in transplant recipients. This study is significant since detailed analysis of cytokines was performed in kidney transplant patients pre- and post-transplant to assess the impact of graft implantation. Twenty patients with mean age of 35 years and comprising 8 females who underwent renal transplantation were included in the study. The mean follow-up time for the study cohort was 5 months. Using a multiplex microassay, twelve cytokines [IL-1a, IL-1b, IL-2, IL-4, IL-6, IL-7, IL-8, IL-10, IL-12, granulocyte–macrophage colony-stimulating factor, IFN-g and tumour necrosis factor] were measured simultaneously before and after transplant. A strong pro-inflammatory response was seen as the levels of circulating IL-1b (p

Published
2013

47. Cytomegalovirus Infection in Ireland

Author

Hassan, Jaythoon, primary, O’Neill, Derek, additional, Honari, Bahman, additional, De Gascun, Cillian, additional, Connell, Jeff, additional, Keogan, Mary, additional, and Hickey, David, additional

Published
2016
Full Text
View/download PDF

48. Human IFNAR2 deficiency: Lessons for antiviral immunity

Author

Duncan, Christopher J. A., primary, Mohamad, Siti M. B., additional, Young, Dan F., additional, Skelton, Andrew J., additional, Leahy, T. Ronan, additional, Munday, Diane C., additional, Butler, Karina M., additional, Morfopoulou, Sofia, additional, Brown, Julianne R., additional, Hubank, Mike, additional, Connell, Jeff, additional, Gavin, Patrick J., additional, McMahon, Cathy, additional, Dempsey, Eugene, additional, Lynch, Niamh E., additional, Jacques, Thomas S., additional, Valappil, Manoj, additional, Cant, Andrew J., additional, Breuer, Judith, additional, Engelhardt, Karin R., additional, Randall, Richard E., additional, and Hambleton, Sophie, additional

Published
2015
Full Text
View/download PDF

50. Homozygosity for HLA Group 2 Alleles Predicts Treatment Failure with Interferon-α and Ribavirin in Chronic Hepatitis C Virus Genotype 1 Infection

Author

Collison, Meadhbh, primary, Chin, Jun Liong, additional, Abu Shanab, Ahmed, additional, Mac Nicholas, Ross, additional, Segurado, Ricardo, additional, Coughlan, Suzie, additional, Connell, Jeff, additional, Carr, Michael J., additional, Merriman, Raphael B., additional, McCormick, P. Aiden, additional, and Hall, William W., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results